The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma
CONCLUSIONS: PD-L1 expression on tumor cells, CD8+ T cell infiltration, and TP53 mutation status may help identify patients with early-stage NSCLC susceptible to recurrence after adjuvant chemotherapy.PMID:38651033 | PMC:PMC11033192 | DOI:10.1016/j.jtocrr.2024.100658 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Hiroaki Kanemura Toshihide Yokoyama Ryu Nakajima Atsushi Nakamura Hiroaki Kuroda Yoshitaka Kitamura Hiroyasu Shoda Nobuaki Mamesaya Yoshihiro Miyata Tatsuro Okamoto Kyoichi Okishio Masahide Oki Yuichi Sakairi Toyofumi Fengshi Chen-Yoshikawa Tadashi Aoki T Source Type: research
Human NLRC4 promotes cancer survival and is associated to type-I interferon signaling and immune infiltration
J Clin Invest. 2024 Apr 23:e166085. doi: 10.1172/JCI166085. Online ahead of print.ABSTRACTThe immune system can control cancer progression. However, even though some innate immune sensors of cellular stress are expressed intrinsically in epithelial cells, their potential role in cancer aggressiveness and subsequent overall survival in humans is mainly unknown. Here, we show that NLR family CARD Domain Containing 4 (NLRC4) is downregulated in epithelial tumor cells of colorectal cancer (CRC) patients by using spatial tissue imaging. Strikingly, only the loss of tumor NLRC4 but not stromal is associated with poor immune infi...
Source: Clinical Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Charlotte Domblides Steven Crampton Hong Liu Juliet M Bartleson Annie Nguyen Claudia Champagne Emily E Landy Lindsey Spiker Christopher Proffitt Sunil Bhattarai Anissa P Grawe Matias Fuentealba Valenzuela Lydia Lartigue Isabelle Mahouche Jeremy Dupaul-Chi Source Type: research
Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study
CONCLUSIONS: Utilizing the split-course hypo-RT and hypo-boost approach, a fraction dose of 5Gy to a total dose of 60Gy, combined with concurrent chemotherapy and subsequent cICI, was well-tolerated, and yielded promising ORR and survival outcomes.PMID:38652815 | DOI:10.1158/1078-0432.CCR-23-3600 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Rui Zhou FangJie Liu HongMei Zhang DaQuan Wang PengXin Zhang ShiYang Zheng YiMei Liu Li Chen JinYu Guo YingYi Zou Yu-Ming Rong Hui Liu Bo Qiu Source Type: research
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
CONCLUSIONS: Phosphoproteomic analysis may help elucidate the mechanisms of resistance to molecular-targeted therapies in lung cancer. Mutual phosphorylation of FAK and Src is involved in osimertinib resistance. Thus, FAK and Src inhibition may be novel treatment strategies for osimertinib-resistant NSCLC.PMID:38646155 | PMC:PMC11031815 | DOI:10.1016/j.jtocrr.2024.100668 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Takehiro Tozuka Rintaro Noro Keisuke Yoshida Satoshi Takahashi Mariko Hirao Kuniko Matsuda Yasuhiro Kato Shinji Nakamichi Susumu Takeuchi Masaru Matsumoto Akihiko Miyanaga Shinobu Kunugi Kazufumi Honda Jun Adachi Masahiro Seike Source Type: research
Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
Int J Clin Oncol. 2024 Apr 22. doi: 10.1007/s10147-024-02525-z. Online ahead of print.ABSTRACTThe biomarker-oriented chemo-immunotherapy is useful and promising in the development of new anticancer agents, since the responders can be enriched by selecting patients with biomarkers. Compared to colorectal and lung cancers, the development of biomarker-driven molecular-targeted therapeutics for gastric cancers has been straggled. However, several new biomarkers in gastric cancers have been discovered and clinical trials in enrichment design with certain biomarkers have been conducted. Therefore, there are currently several tr...
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Koji Kono Shotaro Nakajima Kosaku Mimura Source Type: research
Obstructive sleep apnea severity, circulating biomarkers, and cancer risk
CONCLUSIONS: OSA severity was an independent risk factor for cancer. Furthermore, two circulating markers were significantly associated with cancer risk. If these preliminary findings can be reproduced in other cohorts, biomarkers could potentially be used to prognosticate OSA patients with respect to cancer risk.PMID:38648119 | DOI:10.5664/jcsm.11170 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: A J Hirsch Allen Tetyana Kendzerska Parveen Bhatti Rachel Jen Renelle Myers Mohammadreza Hajipour Stephan F van Eeden Najib Ayas Source Type: research
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
CONCLUSION: Liposomal irinotecan and topotecan demonstrated similar median OS and PFS in patients with relapsed SCLC. Although the primary end point of OS was not met, liposomal irinotecan demonstrated a higher ORR than topotecan. The safety profile of liposomal irinotecan was consistent with its known safety profile; no new safety concerns emerged.PMID:38648575 | DOI:10.1200/JCO.23.02110 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: David R Spigel Afshin Dowlati Yuanbin Chen Alejandro Navarro James Chih-Hsin Yang Goran Stojanovic Maria Jove Patricia Rich Zoran G Andric Yi-Long Wu Charles M Rudin Huanyu Chen Li Zhang Stanley Yeung Fawzi Benzaghou Luis Paz-Ares Paul A Bunn RESILIENT Tr Source Type: research
Dosimetric Impact of Delineation and Motion Uncertainties on the Heart and Substructures in Lung Cancer Radiotherapy
CONCLUSION: Radiotherapy dose uncertainties from delineation variations and respiratory-related heart motion were quantified using a cardiac substructure automatic segmentation tool. This predicts the 'dose range' where doses to structures are most likely to fall, rather than single DVH curves. This enables consideration of these uncertainties in cardiotoxicity research and for future plan optimisation. The tool was designed for cardiac structures, but similar methods are potentially applicable to other OARs.PMID:38649309 | DOI:10.1016/j.clon.2024.04.002 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: V Chin R N Finnegan P Chlap L Holloway D I Thwaites J Otton G P Delaney S K Vinod Source Type: research
Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
CONCLUSIONS: The incidence and risk factors of HPD varied with different definitions, but mHPD identified more cases with poor outcomes. This comprehensive approach may enhance the identification of at-risk patients and lead to a better understanding of HPD in lung cancer during immunotherapy.PMID:38644088 | DOI:10.1016/j.cllc.2024.03.001 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 21, 2024 Category: Cancer & Oncology Authors: Trie Arni Djunadi Youjin Oh Jeeyeon Lee Jisang Yu Liam Il-Young Chung Yeunho Lee Leeseul Kim Timothy Hong Soowon Lee Zunairah Shah Joo Hee Park Sung Mi Yoon Young Kwang Chae Source Type: research
Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice
Clin Exp Med. 2024 Apr 20;24(1):80. doi: 10.1007/s10238-024-01342-y.ABSTRACTPeritoneal mesothelioma (PeM) is an aggressive tumor with limited treatment options. The current study aimed to evaluate the value of next generation sequencing (NGS) of PeM samples in current practice. Foundation Medicine F1CDx NGS was performed on 20 tumor samples. This platform assesses 360 commonly somatically mutated genes in solid tumors and provides a genomic signature. Based on the detected mutations, potentially effective targeted therapies were identified. NGS was successful in 19 cases. Tumor mutational burden (TMB) was low in 10 cases, ...
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Job P van Kooten Michelle V Dietz Hendrikus Jan Dubbink Cornelis Verhoef Joachim G J V Aerts Eva V E Madsen Jan H von der Th üsen Source Type: research
Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China
CONCLUSION: Patients with lung cancer require more ICU care due to critical complications and the overall survival prognosis is poor. Colorectal cancer may benefit more from ICU management. This information may be considered in ICU admission and treatment strategies.PMID:38642154 | PMC:PMC11032264 | DOI:10.1007/s00432-024-05727-0 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Wensheng Liu Dongmin Zhou Li Zhang Mingguang Huang Rongxi Quan Rui Xia Yong Ye Guoxing Zhang Zhuping Shen Cancer Critical Care Medicine Committee of the Chinese Anti-Cancer Association Source Type: research
Automated treatment planning for whole breast irradiation with individualized tangential IMRT fields
CONCLUSIONS: Although our attempt to correlate patient anatomical features with planning strategy using machine learning tools was unsuccessful, the resulting dosimetric outcomes proved satisfactory. Our algorithm consistently produced high-quality plans, offering significant time and efficiency advantages.PMID:38642406 | DOI:10.1002/acm2.14361 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Giulianne Rivelli Rodrigues Zaratim Ricardo Gomes Dos Reis Marcos Ant ônio Dos Santos Nathalya Ala Yagi Luis Felipe Oliveira E Silva Source Type: research
Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics
J Clin Pharmacol. 2024 Apr 19. doi: 10.1002/jcph.2435. Online ahead of print.ABSTRACTTrilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of tr...
Source: Clinical Lung Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Chao Li Richard A Preston Emily Dumas Andrew Beelen Thomas C Marbury Source Type: research
The Effect of Vaccination with Pfizer-BioNTech or CoronaVac on Disease Prognosis Among Hospitalized COVID-19 Patients
CONCLUSION: Among the inpatients with COVID-19, the predictors for mortality were being unvaccinated, older age, cancer, chronic kidney disease, and cardiovascular diseases. Among the vaccinated inpatients, having two doses of the Pfizer-BioNTech vaccine was the only effective protective measure against mortality, and two doses of the CoronaVac vaccine had no significant effect in preventing fatality.PMID:38633010 | PMC:PMC10985826 | DOI:10.36519/idcm.2023.226 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Mustafa G üldan Sena Tu ğana Ateş Sebile Sar ıoğlu Sarp Suyabatmaz Pelin İrkören S üda Tekin Mahir Kapmaz Şiran Keske Önder Ergönül Source Type: research
Age, Gender, and Liver Enzyme Impact Hospital Stay in COVID-19 Minority Patient with Cancer in the USA: Does Race Matters in the Pandemic?
Ann Clin Med Case Rep. 2024;13:7. Epub 2024 Mar 21.ABSTRACTPatients with cancer are known to have a poor prognosis when infected with SARS-CoV-2 infection. We aimed in this study to assess health outcomes in COVID-19 patients with different cancers in comparison to non-cancer COVID-19 patients from different centers in the United States (US). We evaluated medical records of 1,943 COVID-19 Cancer patients from 3 hospitals admitted between December 2019 to October 2021 and compared them with non-cancer COVID-19 patients. Among 1,943 hospitalized COVID-19 patients, 18.7% (n=364) have an active or previous history of cancer. A...
Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: H Ashktorab G Oskrochi S R Challa L G Chirumamilla S Saroya S Dusmatova N Shayegh V Nair K Senthilvelan D Byer N Morrison B Grossi A Barclay T Smith K Watson M Rashid R Rashid M Deverapalli G Latella J M Carethers A Youssef H Brim Source Type: research
